Literature DB >> 10497987

Synergism of benflumetol and artemether in Plasmodium falciparum.

M Hassan Alin1, A Björkman, W H Wernsdorfer.   

Abstract

Using a continuous in vitro culture system, the sensitivity of Plasmodium falciparum to artemether and a new antimalarial drug, benflumetol (lumefantrine), alone and in combination, was investigated with a multiresistant strain (T-996) from Thailand and a chloroquine-resistant strain (LS-21) from India. Both strains showed similar 50% inhibitory concentration (IC50) levels with artemether alone or benflumetol alone, but the IC90 was higher in strain T-996 compared with strain LS-21: for artemether, 34.45 and 7.11 nmol/L (10.28 and 2.12 ng/ml of erythrocyte-medium mixture [EMM]), and for benflumetol, 293.03 and 95.61 nmol/L (154.69 and 50.47 ng/ml of EMM). When tested in association at artemether:benflumetol (mol: mol) ratios between 100:1 and 1:100, substantial synergism was seen in both strains, especially at the IC90 and IC99 levels. This phenomenon resembles the synergistic interaction of artemisinin derivatives and mefloquine, first observed in laboratory models and later confirmed in clinical experience.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10497987     DOI: 10.4269/ajtmh.1999.61.439

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum.

Authors:  S Gupta; M M Thapar; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum.

Authors:  Quinton L Fivelman; Ipemida S Adagu; David C Warhurst
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

Review 3.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.

Authors:  Richard T Eastman; David A Fidock
Journal:  Nat Rev Microbiol       Date:  2009-11-02       Impact factor: 60.633

4.  Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand.

Authors:  H Noedl; T Allmendinger; S Prajakwong; G Wernsdorfer; W H Wernsdorfer
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  In vitro sensitivity of Plasmodium falciparum and clinical response to lumefantrine (benflumetol) and artemether.

Authors:  P Tanariya; P Tippawangkoso; J Karbwang; K Na-Bangchang; W H Wernsdorfer
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

6.  Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.

Authors:  Rina P M Wong; Sam Salman; Kenneth F Ilett; Peter M Siba; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2011-01-03       Impact factor: 5.191

7.  Synergism between amodiaquine and its major metabolite, desethylamodiaquine, against Plasmodium falciparum in vitro.

Authors:  S T Mariga; J P Gil; C Sisowath; W H Wernsdorfer; A Björkman
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

8.  Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.

Authors:  Peter Starzengruber; Gunther Wernsdorfer; Maria Parizek; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.

Authors:  Maria Parizek; Jeeraphat Sirichaisinthop; Gunther Wernsdorfer; Harald Noedl; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 10.  Coartem: the journey to the clinic.

Authors:  Zulfiqarali G Premji
Journal:  Malar J       Date:  2009-10-12       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.